NASDAQ:EVAX Stock Quote
Evaxion Biotech A/S is a biotechnology company that focuses on the development of innovative immunotherapies and personalized cancer treatments using its proprietary artificial intelligence platform
The company specializes in designing and developing therapeutic vaccines that harness the body's immune system to target and destroy cancer cells. By leveraging advanced machine learning algorithms, Evaxion aims to identify optimal vaccine candidates tailored to individual patients, with the goal of providing more effective and customized treatment options for various types of cancer and infectious diseases.
Frequently Asked Questions
How does Evaxion ensure product safety?
Evaxion follows rigorous safety protocols and regulatory guidelines throughout the product development process. The company conducts preclinical and clinical trials designed to assess the safety and efficacy of its therapeutic candidates, and it collaborates with regulatory authorities to ensure compliance and validation of its findings.
How does Evaxion plan to fund its operations?
Evaxion plans to fund its operations through a combination of public and private investment, including the proceeds from its initial public offering (IPO) and potential collaborations with pharmaceutical companies. The company continues to seek funding opportunities to advance its clinical programs and expand its research initiatives.
How many employees does Evaxion have?
As of the latest reports, Evaxion employs a dynamic team of scientists, researchers, and professionals reflecting its commitment to innovation in biotechnology. The company's workforce is focused on advancing its product pipeline, enhancing research capabilities, and maintaining operational excellence.
On which exchange are Evaxion's ADS listed?
Evaxion's American Depositary Shares are listed on the Nasdaq stock exchange under the ticker symbol 'EVAX.' This listing allows U.S. investors to easily purchase and trade shares of the company as it progresses through its clinical developments.
What are American Depositary Shares (ADS)?
American Depositary Shares (ADS) represent shares of a foreign company that are traded on U.S. exchanges. Each ADS typically corresponds to a specific number of the company's shares traded in its home market. For Evaxion, ADS allows U.S. investors to invest in the company while facilitating easier trading and compliance with local regulations.
What are the company's strategic goals?
Evaxion aims to advance its pipeline of immunotherapies and vaccines, move its lead product candidates through clinical trials, and ultimately achieve regulatory approval for commercialization. The company also seeks to establish strategic partnerships to enhance its research capabilities and broaden its market reach.
What are the main challenges Evaxion faces?
Like many biotechnology firms, Evaxion faces several challenges, including regulatory hurdles for drug approval, competition from established pharmaceutical companies, and securing sufficient funding to continue its clinical trials and research. The company must also effectively manage its resources and timelines to bring its therapies to market.
What are the potential market opportunities for Evaxion?
Evaxion operates in high-potential market segments, including cancer treatment and infectious disease vaccines, particularly as the global demand for personalized medicine and innovative therapies continues to rise. The expanding oncology market and ongoing need for effective vaccines against emerging infectious diseases present significant opportunities for the company.
What collaborations does Evaxion have?
Evaxion actively seeks collaborations with other biotech and pharmaceutical companies, research institutions, and academic organizations to bolster its development capabilities. These partnerships often facilitate shared expertise in drug development, pooling of resources, and accelerating the pace of bringing innovative therapies to market.
What does Evaxion Biotech A/S do?
Evaxion Biotech A/S is a clinical-stage biotechnology company specializing in the development of novel immunotherapies and vaccines for the treatment of cancer and infectious diseases. The company leverages its proprietary AI-based platform to identify and develop unique therapeutic candidates that can stimulate the immune system to effectively target and destroy cancer cells.
What is Evaxion's lead product candidate?
Evaxion's lead product candidate is EVA101, an immunotherapy designed to target solid tumors. This therapy aims to stimulate the patient's immune system to recognize and attack cancer cells, providing a personalized approach to cancer treatment. The company is currently conducting clinical trials to evaluate its efficacy and safety.
What is Evaxion's pipeline of products?
Evaxion has a diverse pipeline of immunotherapies and vaccines, including various candidates targeting different cancers and infectious diseases. The company is in various stages of development, from preclinical research to clinical trials, focused on deploying its AI-based technology to create innovative treatments.
What is the focus of Evaxion's research and development?
Evaxion's primary focus is on the development of personalized cancer immunotherapies and vaccines against infectious diseases such as COVID-19. Their research employs advanced computational methods to design therapies that can be tailored to the specific genetic makeup of individual patients or pathogens.
What is the role of the board of directors at Evaxion?
The board of directors at Evaxion Biotech provides strategic oversight and governance, guiding the company’s strategic decisions and ensuring accountability. The members typically have extensive experience in biotechnology, finance, and corporate governance, which aids in navigating the complex biotech landscape.
What is the significance of Evaxion's AI technology?
Evaxion's AI technology plays a crucial role in its research and development processes, enabling the company to analyze vast datasets and predict immune responses to various antigens. This capability accelerates the selection of promising therapeutic candidates and enhances the personalization of treatments, which can ultimately lead to more effective therapies.
What is the technology platform used by Evaxion?
Evaxion utilizes a proprietary AI-based technology platform called 'PIONEER.' This platform is designed to accelerate the discovery of novel therapeutic candidates by predicting how the immune system will respond to different antigens, allowing for the rapid development of personalized immunotherapies.
When was Evaxion Biotech founded?
Evaxion Biotech was founded in 2018 in Denmark. Since its inception, the company has dedicated itself to harnessing cutting-edge technology for drug development, placing a strong emphasis on innovative solutions for previously challenging medical conditions.
Where is Evaxion Biotech headquartered?
Evaxion Biotech is headquartered in Copenhagen, Denmark. The strategic location allows the company to tap into the vibrant biotech ecosystem of Scandinavia, which is known for its strong emphasis on research, development, and innovation in the life sciences.
Who are Evaxion's competitors?
Evaxion competes with other biotechnology firms and pharmaceutical companies that focus on immunotherapy and vaccine development. Notable competitors include larger firms with established immuno-oncology pipelines, smaller biotech companies with innovative approaches, and research institutions working on similar therapeutic strategies.
What is the current price of Evaxion Biotech A/S - American Depositary Share?
The current price of Evaxion Biotech A/S - American Depositary Share is 1.670
When was Evaxion Biotech A/S - American Depositary Share last traded?
The last trade of Evaxion Biotech A/S - American Depositary Share was at 1:50 pm EDT on April 2nd, 2025
What is the market capitalization of Evaxion Biotech A/S - American Depositary Share?
The market capitalization of Evaxion Biotech A/S - American Depositary Share is 63.29M
How many shares of Evaxion Biotech A/S - American Depositary Share are outstanding?
Evaxion Biotech A/S - American Depositary Share has 37.90M shares outstanding.